In the following, the online help texts for all data entry fields provided with any Endpoint summary record for this IUCLID section are listed. As to whether and to what extent endpoint summaries should be prepared, refer to the relevant guidance for the respective chemical programme, e.g., the Technical Guidance Document (TGD) on preparing the Chemical Safety Report under REACH in its most recent version.
For technical guidance on how to manage Endpoint summary records, see How to manage Endpoint summary records in sections 4 - 10, respectively. For details on data types, see What data types are available for input fields and how are they used?.
Enter a full short description of the most relevant endpoint data. This includes in principle the summary information that is compiled e.g. in the OECD Full SIDS Summary format or other endpoint summary formats. Provide only the most relevant details, which could be, depending on the cases, the test guideline used, test organism and exposure duration. Normally no reliability score needs to be indicated as it can be assumed that the studies identified are valid (reliability score 1 or 2). If this is not the case (for instance if the reliability of a published study cannot be assigned or if several less valid studies are used for a weight of evidence analysis), the reliability indicators should be specified.
Also several key studies can be referenced as applicable. However, the characterisation of the endpoint data should be kept as concise as possible. Examples of what could be entered here are as follows:
- Melting point: 54.6-55.8 °C at 1,013 hPa
- Water solubility: completely miscible
- pH: 6.9 (80 mg/l water) at 20°C (OECD TG105)
- Oxidation reduction potential: no data available
- Phototransformation in air: T1/2 = 9.32 x 10-2 yr (sensitizer: OH radical) (AOP Win v 1.86)
- Biodegradation in water: screening tests: Not readily biodegradable: 0 - 8% (BOD) in 28 days, 0 - 1% (HPLC) in 28 days (OECD TG 301C)
- Short-term toxicity to fish:
LC50 (96h) < 100 mg/l for Pimephales promelas (OECD TG 203)
LC50 (48h) = 3.2 mg/l for Oryzias latipes (OECD TG 203)
- Acute toxicity:
Dermal: LD50: > 2,000 mg/kg for rat (limit test)
- Genetic toxicity:
In vitro:
Gene mutation (Bacterial reverse mutation assay / Ames test): S. typhimurium TA 100: positive with and without metabolic activation; TA 1535: positive without metabolic activation (equivalent to OECD TG 471)
The field(s) under this heading (if provided) can be optionally completed in order to specify the key parameter(s) that may subsequently be used in the chemical safety assessment, classification and labelling or other. In order to enable the use of any specific software, only a minimum number of structured and hence, searchable fields are provided, in many cases only one.
Key parameters are intended to condense the data summarised in field "Full short description of relevant endpoint data" to one single numeric value or concluding remark (e.g. negative / positive) chosen from a drop-down list. Where a numeric field is provided, only a clear value can be entered, that is, no range and no less than or greater than qualifiers. Conversion to a predefined unit as indicated in the field label (e.g. mg/L) may be required.
If the key value is no clear number, but a range or preceded by <, <=, >, or >=, you may either leave this field empty or make up a value you consider most appropriate for the intended subsequent purpose. The rationale for any user-derived values should be described in field "Discussion" for the sake of transparency. Some non-exhaustive examples of user-derived parameters are as follows:
- Aquatic short-term L(E)C50 >100 mg/L (e.g. because only tested up to water solubility of the substance): it may be appropriate to assume 100 mg/L as worst case value.
- Aquatic long-term LOEC 1 mg/L (>10 and <20% effect): calculate NOEC as LOEC/2 and enter 0.5 mg/L in the field for NOEC.
- Acute oral LD50 >2000 mg/kg b.w. (because no LD50 was achieved in a limit test): enter 2000 mg/kg b.w.
In this rich text field, describe the assessment you have made for the given endpoint. Provide the rationale for the choice of the key study(ies) and the choice of the key parameter that, according to your judgement, characterise the endpoint. This includes a discussion of the key information identified and in some instances of studies which are considered to be unreliable, but give critical results. A discussion as to why they were discarded in favour of other studies should then be included. Vice versa, a weight of evidence analysis based on less reliable data or use of published data, the reliability of which cannot be judged because of limited reporting, should be justified.
If several studies were identified to be relevant for the assessment, discuss possible reasons for differing results if any, e.g. differences in purity / impurities of the test substance used, differences in the methods and test conditions, etc.
Enter a full short description of the most relevant endpoint data. This includes in principle the summary information that is compiled e.g. in the OECD Full SIDS Summary format or other endpoint summary formats. Provide only the most relevant details, which could be, depending on the cases, the test guideline used, test organism and exposure duration. Normally no reliability score needs to be indicated as it can be assumed that the studies identified are valid (reliability score 1 or 2). If this is not the case (for instance if the reliability of a published study cannot be assigned or if several less valid studies are used for a weight of evidence analysis), the reliability indicators should be specified.
Also several key studies can be referenced as applicable. However, the characterisation of the endpoint data should be kept as concise as possible. Examples of what could be entered here are as follows:
- Melting point: 54.6-55.8 °C at 1,013 hPa
- Water solubility: completely miscible
- pH: 6.9 (80 mg/l water) at 20°C (OECD TG105)
- Oxidation reduction potential: no data available
- Phototransformation in air: T1/2 = 9.32 x 10-2 yr (sensitizer: OH radical) (AOP Win v 1.86)
- Biodegradation in water: screening tests: Not readily biodegradable: 0 - 8% (BOD) in 28 days, 0 - 1% (HPLC) in 28 days (OECD TG 301C)
- Short-term toxicity to fish:
LC50 (96h) < 100 mg/l for Pimephales promelas (OECD TG 203)
LC50 (48h) = 3.2 mg/l for Oryzias latipes (OECD TG 203)
- Acute toxicity:
Dermal: LD50: > 2,000 mg/kg for rat (limit test)
- Genetic toxicity:
In vitro:
Gene mutation (Bacterial reverse mutation assay / Ames test): S. typhimurium TA 100: positive with and without metabolic activation; TA 1535: positive without metabolic activation (equivalent to OECD TG 471)
The field(s) under this heading (if provided) can be optionally completed in order to specify the key parameter(s) that may subsequently be used in the chemical safety assessment, classification and labelling or other. In order to enable the use of any specific software, only a minimum number of structured and hence, searchable fields are provided, in many cases only one.
Key parameters are intended to condense the data summarised in field "Full short description of relevant endpoint data" to one single numeric value or concluding remark (e.g. negative / positive) chosen from a drop-down list. Where a numeric field is provided, only a clear value can be entered, that is, no range and no less than or greater than qualifiers. Conversion to a predefined unit as indicated in the field label (e.g. mg/L) may be required.
If the key value is no clear number, but a range or preceded by <, <=, >, or >=, you may either leave this field empty or make up a value you consider most appropriate for the intended subsequent purpose. The rationale for any user-derived values should be described in field "Discussion" for the sake of transparency. Some non-exhaustive examples of user-derived parameters are as follows:
- Aquatic short-term L(E)C50 >100 mg/L (e.g. because only tested up to water solubility of the substance): it may be appropriate to assume 100 mg/L as worst case value.
- Aquatic long-term LOEC 1 mg/L (>10 and <20% effect): calculate NOEC as LOEC/2 and enter 0.5 mg/L in the field for NOEC.
- Acute oral LD50 >2000 mg/kg b.w. (because no LD50 was achieved in a limit test): enter 2000 mg/kg b.w.
In this rich text field, describe the assessment you have made for the given endpoint. Provide the rationale for the choice of the key study(ies) and the choice of the key parameter that, according to your judgement, characterise the endpoint. This includes a discussion of the key information identified and in some instances of studies which are considered to be unreliable, but give critical results. A discussion as to why they were discarded in favour of other studies should then be included. Vice versa, a weight of evidence analysis based on less reliable data or use of published data, the reliability of which cannot be judged because of limited reporting, should be justified.
If several studies were identified to be relevant for the assessment, discuss possible reasons for differing results if any, e.g. differences in purity / impurities of the test substance used, differences in the methods and test conditions, etc.
In the following, the online help texts for all data entry fields provided with any Endpoint study record for this IUCLID section are listed. For sections 4 to 10, these guidance notes are completely based on the so-called OECD Harmonised Templates (see Rationale behind IUCLID Endpoint Study Records - OECD harmonised templates in chapter chapter D.4.7.1 What is an Endpoint study record?)
IUCLID per se does not prescribe how detailed the study summaries should be recorded. Refer to the relevant guidance for the respective chemical regulatory programme thereof.
For technical guidance on how to manage Endpoint study records, see chapter D.4.7 How to manage Endpoint study records in sections 4 - 13. For details on data types, see chapter D.4.5 What data types are available for input fields and how are they used?
Under this main heading, fields are subsumed for identifying the purpose of the record (e.g., "key study"), the type of result (e.g., "experimental study"), data waiving indication (if any), reliability indication, and flags for indicating the regulatory purpose envisaged and/or any confidentiality restrictions. This kind of data characterise the relevance of a study summary and are therefore displayed on top of each Endpoint Study Record. For detailed guidance, refer to chapter D.4.7.7.1 Administrative data.
Indicate the bibliographic reference of the study report or publication the study summary is based on. Always enter the primary reference in the first block of fields (i.e. Sort no. = 1), if there are more than one reference to be cited. Copy this block of fields for specifying any other references related to this record (e.g. report of a preliminary study or other documentation). If results of a study report have been published, indicate the full citation of that publication(s) in addition to the reference of the original study.
Table E.404. Field Descriptions
| Reference type | Indicate the type of reference, e.g. "Study report" or "Publication". Select "Other company data" to characterise any unpublished information from a company other than a study report. Select "Grey literature" for any other unpublished information or "other:" and specify. |
| Author(s) (or transferred reference) (Author) | For ease of sorting and searchability use following convention: Surname, Initial (Example 1: White D, Ruehl KJ, Borman SA & Little J. Example 2: Hartley M & Murray W (avoid unnecessary full-stops, commas)). If no individuals are cited as authors, enter name of company or organisation or "Anon." as appropriate. Note that the complete bibliographic reference may appear in this field after migration of unstructured data from existing databases. |
| Year | Enter year of study report or publication. For a study report this field should be completed to include it in any searches, regardless of whether the complete date is given in field "Report date". |
| Title | Include the title of the report. For publications, include the title of the article of a journal or article/chapter of a book (e.g. handbook). |
| Bibliographic source | Not relevant for any study report. For publications or any other literature source (grey literature) specify the following type of information: (i) Title of scientific journal or book (e.g. if handbook); (ii) Volume of journal; (iii) Editor, publisher, place of publication for books or articles in books; (iv) Pagination. Example 1 (journal): J. Agric. Food Chem. 38: 215-227 Example 2 (handbook): In: Lyman WJ (ed.) Handbook of chemical property estimation methods. Environmental behavior of organic compounds. McGraw-Hill Book Company 15.1-15.34, New York. |
| Testing laboratory | Either manually enter the name of the testing laboratory or select it from the picklist. In either case, editing is possible. |
| Report no. | Specify the report number allocated by the testing laboratory. Note that any company-specific study number should be included in the respective field. |
| Owner company | Either manually enter the identity of the company who owns the data or select it from the picklist. In either case, editing is possible. |
| Company study no. | Specify any company study no. if there is such a number and if it is different from the report no. of the testing laboratory. Otherwise leave field empty. |
| Report date | Specify the complete date of the study report, e.g. "2005-05-12" for 12 May 2005. Note that subfield "Year" should be completed in any case for sorting and searching purposes. |
Select appropriate indication for data access. Enter "Not applicable" if the summary consists of information that is commonly accessible such as guidance on safe use.
Indicate as appropriate. Note: "yes" should be selected only if "Data submitter is data owner" or "Data submitter has Letter of Access". Options "yes, but willing to share" or "yes, but not willing to share" may be relevant for specific regulatory programmes where the submitter is requested to indicate whether he is willing to share studies (e.g. with vertebrates).
In the supplementary remarks field, include an explanation as appropriate, i.e. justification for denial of sharing the corresponding study or refer to a document attached that provides justification (e.g. "for justification see attached document X")
A cross-reference can be included to indicate that the same study is recorded in another record. Indicate the respective chapter and record ID and enter relevant explanatory text. This may be useful if specific endpoints of a given study are described in another chapter (e.g. results on reproduction toxicity in case of a combined repeated dose / reproduction toxicity study) or if more than one experiment is described by the same study report, but included in separate records.
Check with the relevant guidance document whether all the methodology details must be repeated or whether a cross-reference to the same study in another chapter may suffice.
Note that any such cross-reference may become useless if a record is either printed or exchanged on its own.
Indicate if study was in vivo or in vitro test. If in vitro test, describe study design in field "Any other information on materials and methods incl. tables" and the results in field "Any other information on results incl. tables". If a specific template for in vitro assays is provided include the data in that template instead.
Indicate according to which test guideline the study was conducted. If no test guideline was explicitly followed, but the methodology used is equivalent or similar to a specific guideline, you can indicate so in the "Qualifier" subfield preceding the field "Guideline".
Copy this block of fields for specifying more than one guideline (e.g. US EPA in addition to OECD guideline).
Table E.405. Field Descriptions
| Qualifier | Select appropriate qualifier, i.e. - "according to" (if a given test guideline was followed); - "equivalent or similar to" (if no test guideline was explicitly followed, but the methodology is equivalent or similar to a specific guideline); - "no guideline followed" (if none of above qualifiers apply. If so, fill in field "Principles of method if other than guideline"); - "no guideline available" (if so, fill in field "Principles of method if other than guideline"). - "no guideline required" (if so, fill in field "Principles of method if other than guideline"). |
| Guideline | Select the applicable test guideline, e.g. "OECD Guideline xxx". If the test guideline used is not listed, choose "other guideline:" and specify the test guideline in the related text field. In this text field, you can also enter any remarks as applicable, particularly: - To include any other title of the test guideline draft used, a subtitle, another version or update number and the year of update (For instance, different titles and/or numbers may exist for a given EU test guideline.); - To indicate if a the study was performed prior to the adoption of the test guideline specified; - To indicate if the methodology used was based on an extension of the test guideline specified. |
| Deviations from guideline (Deviations) | For robust study summaries or as requested by the regulatory programme, indicate if there are any deviations from the test guideline specified. If "yes" is selected, only briefly state relevant deviations in the supplementary remarks field (e.g. "other species used"); details should be described in the respective fields of the section MATERIALS AND METHODS. |
If no guideline was followed, include a description of the principles of the test protocol or estimated method used in the study. Details should be entered in appropriate distinct fields of section MATERIALS AND METHODS if available. Also provide a justification for using this method if appropriate.
If an estimation method was used (to be indicated in field "Test result type") state the equation(s) and/or computer software or other methods applied to calculate the value(s).
Indicate whether the study was conducted following Good Laboratory Practice or not. Select "yes (incl. certificate)" if a GLP certificate of a test facility is available. Select "yes" if a GLP compliance statement is available, but no information on a GLP certificate. You can give an explanation in the supplementary remarks field, e.g. for explaining why GLP was not complied with or for specifying which (national) GLP was followed.
Indicate if the test material used in the study is equivalent to the submission substance identity. If "yes" is selected, the corresponding identity is automatically entered in the subsequent block of fields "Test material identity".
If "no" is selected, identify the test material in the subsequent block of fields "Test material identity". In this case, also make sure that the information entered in field "Study result type" is consistent, i.e. "read-across from supporting substance (structural analogue or surrogate)".
NOTE: If a completed record is used for another submission, you may have to update both fields "Study result type" and "Test material equivalent to submission substance identity".
If the identity of the test material used for this study is not included in this block of fields automatically, indicate the identity for one or more appropriate identifiers, e.g. CAS number, CAS name, IUPAC name. Copy this block of fields as appropriate.
If another than the submission substance identity was selected erraneously, go back to field "Test material equivalent to submission substance identity" and select "yes". This will prompt automatic entry of the respective identifiers.
Table E.406. Field Descriptions
| Identifier | Select an appropriate identifier from drop-down list, e.g. "CAS number". Use "Other:" and specify, if identity according to a standard identifier is not known or if an additional chemical name or number is provided. |
| Identity | Select the corresponding substance identity from drop-down list or enter manually if the identity is not available from the list or if no list is provided for the type of identifier selected. |
Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Note that any information that can be claimed confidential should be included in the subsequent field "Confidential details on test material".
Explanations:
- Name of test material (as cited in study report): only if different from any other identifiers provided in the preceding fields.
- Molecular formula (if other than submission substance): specify
- Molecular weight (if other than submission substance): specify
- Smiles notation (if other than submission substance): provide if available
- InChl (if other than submission substance): provide if available
- Structural formula attached as image file (if other than submission substance): see Fig.: only if different from submission substance. Indicate Fig. no. if a file is attached in field "Attached document", e.g. state "see Fig. 1".
- Substance type: indicate whether pure active substance, technical product, formulation or other.
- Physical state: indicate "gas", "solid" or "liquid" only if different from submission substance or if substance can occur in different physical states.
- Analytical purity: specify in %
- Impurities (identity and concentrations): specify
- Composition of the test material, percentage of components: specify if applicable
- Isomers composition: specify if applicable
- Purity test date: provide if available
- Lot/batch No.: provide if available
- Expiration date of the lot/batch: provide if available
- Radiochemical purity (if radiolabelling): specify if applicable
- Specific activity (if radiolabelling): specify if applicable
- Locations of the label (if radiolabelling): specify if applicable
- Expiration date of radiochemical substance (if radiolabelling): specify if applicable
- Storage condition of test substance: specify if applicable
- Stability under test conditions: indicate if available
Enter any confidential information on the test material in this separate field. Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Explanations:
- Analytical purity: specify in %
- Impurities (identity and concentrations): specify
- Composition of the test material, percentage of components: specify if applicable
- Purity test date: provide if available
- Lot/batch No.: : provide if available
- Expiration date of the lot/batch: : provide if available
- Isomers composition: specify if applicable
Select as appropriate. For in vitro tests, indicate the species used as source of the test system. If not available from picklist, select "other" and specify.
NOTE: Although species "human" is provided in the picklist for specifying the source of in vitro test systems as applicable, human data should be reported in an appropriate subsection of section "Exposure related observations", particularly subsection "Sensitisation data".
It can be useful to document, in section "Skin sensitisation", that human data are provided by creating a record and referring to the human data in field "Cross-reference to same study". This could be relevant if lack of animal experiments is defended by the availability of data on experience with human exposure.
Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) as to whether human data should be referenced in the appropriate endpoint summary record.
Select strain as appropriate. If not available from picklist, select "other" and specify.
Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Explanations:
- Diet: Describe type of diet (e.g. conventional laboratory diet / caloric restriction) and whether it was provided ad libitum.
- Water: Describe type (e.g. drinking water) and whether it was provided ad libitum.
- IN-LIFE DATES: If required, specify the in-life dates (i.e. the phase of a study following treatment in which the test system is alive/growing).
Select "unchanged (no vehicle)" if none was used or select vehicle used if any.
For each exposure phase (i.e. induction/challenge) provide the doses / concentrations of the test substance applied including unit (i.e. undiluted, %, % active substance, FCA, mg, g).
Provide number of animals per dose or range if different numbers were used, e.g. "10 (controls), 10-20 (in test groups)".
For traditional sensitisation tests, describe any range finding tests (pilot study) and for the main study the induction and challenge procedures including the type of information given in the freetext template. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Example for Freund's Complete Adjuvant (FCA) test (partly adopted from OECD 406):
A. INDUCTION EXPOSURE
- No. of exposures: 5
- Exposure period: -
- Test groups: TS in FCA
- Control group: FCA only
- Site: R flank
- Frequency of applications: every 2nd day
- Duration: 0-8 d
- Concentrations: same throughout
B. CHALLENGE EXPOSURE
- No. of exposures: 2
- Day(s) of challenge: 22 & 35
- Exposure period: -
- Test groups: TS
- Control group: TS
- Site: L flank
- Concentrations: 4 different
- Evaluation (hr after challenge): 24, 48, 72
Discuss the use of a challenge (i.e. naive) control group: number and sex of animals, dose for challenge application.
Indicate if positive control substance(s) was/were used. If yes, describe the positive control(s) in supplementary field as appropriate.
Select "unchanged (no vehicle)" if none was used or select vehicle used if any. If the vehicle used is not from the list a rationale must be provided in the supplementary remarks field.
Describe dose selection, i.e. at least 3 consecutive concentrations (100%, 50%, 25% 10%, 5%, 2.5%, 1%, 0.5% etc.) of the test substance.
Provide number of animals per dose or range if different numbers were used, e.g. "4 per group (pooled lymph nodes)" or "5 per group (individual animals used)".
For LLNA, describe details on materials and methods as indicated in the freetext template. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
- Details on radio isotope: to be included in field "Details on test material"
- RANGE FINDING TESTS: Briefly describe compound solubility, irritation and lymph node proliferation response if significant.
MAIN STUDY
- ANIMAL ASSIGNMENT AND TREATMENT: Indicate name of test method used. Comment on criteria used to consider a positive response.
- TREATMENT PREPARATION AND ADMINISTRATION: Describe dose preparation and administration. (e.g. 25 µl of compound x was applied to the entire dorsal surface of each ear of each mouse. The application was repeated on days 2 and 3). On day 6 an injection of 250 µl phosphate buffered saline (PBS) containing 20 µCi of 3H-methyl thymidine (3H-TdR) or 250 µl PBS containing 2 µCi of 125 I-iododeoxy-uridine (125IU) and 10-5 M fluorodeoxy-uridine was made into the tail vein of each experimental mouse. Five hours later, the draining Auricular lymph node of each ear was excised into PBS. A single cell suspension of lymph node cells was prepared from each mouse. (describe method of cell suspension). Cells were precipitated with 5% trichloroacetic acid at 4 °C for 18 hours.
Indicate the positive control substance(s) used and give additional remarks in supplementary field as appropriate. Copy this field if more than one substance was used.
Provide the statistical procedures employed (e.g., linear regression analysis to assess dose-response trends; Dunnett¿s test to make pairwise comparisons).
In this field, you can enter any information on materials and methods, for which no distinct field is available, or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
Discuss the positive control results and demonstrate that the laboratory has the capability to identify positive dermal sensitizers.
Record the results of traditional tests at the different readings for each test or control group used. Copy this block of fields as appropriate.
Present the scores from the challenge responses in a table.
Table E.407. Field Descriptions
| Reading | Select from drop-down list. |
| Hours after challenge | Enter numeric value. |
| Group | Select from drop-down list. |
| Dose level | If more than one concentration was tested at challenge, specify the concentration(s) the reading refers to, e.g. "0.15 g of a 10% aqueous solution". Several dose levels can be given if the results reported in this block of fields is the same for all challenge groups, e.g. "0.15 or 0.3 g of a 10% aqueous solution". |
| Number of animals with positive reactions (No. with + reactions) | Enter numeric value. |
| Total number of animals in group (Total no. in group) | Enter numeric value. |
| Clinical observations | Briefly describe relevant clinical observations. |
Briefly describe the results of DPM measurements. Comment on dose-response trends and comparisons with the vehicle control group. Give statistical comparisons of group mean DPMs compared to control. Indicate whether results are from the individual animals or pooled. As appropriate include table(s) in the rich text field "Any other information on results incl. tables". Upload predefined table(s) if any or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1").
Note: Specific tables may be required. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Briefly describe the calculated SI and EC3. Calculation of µg/cm2 dose applied. As appropriate include table(s) in the rich text field "Any other information on results incl. tables". Upload predefined table(s) if any or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1").
Note: Specific tables may be required. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
In this field, you can enter any other remarks on results. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: Both the "Materials and methods" section and "Results" section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
In this field, you can enter any overall remarks or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
Attach any background document that cannot be inserted in any rich text editor field, particularly image files (e.g. an image of a structural formula).
Copy this block of fields for attaching more than one file.
Table E.408. Field Descriptions
| Attached document | Upload file by clicking the upload icon. As appropriate, enter any additional information, e.g. language. The file name is displayed after uploading the document. |
| Remarks | As appropriate, include remarks, e.g. a short description of the content of the attached document if the file name is not self-explanatory. |
If required, an electronic copy of the full study report can be attached as WORD, pdf or other document type, which will not be integrated in any report, but must be handled as separate files.
Note: In the export administration you can indicate whether the attached files should be included in the data export or not.
Indicate overall interpretation of test results as given in the study report or as concluded by the submitter. Use supplementary remarks field for indicating if conclusions originally reported were changed by submitter.
Note that a classification in the strict sense is normally not based on an individual study, but includes a weight of evidence evaluation of all relevant data. However, if a single study is used for a classification, you can indicate this In the supplementary remarks field.
If required by the respective national/regional programme, briefly summarise the relevant aspects of the study including the conclusions reached. If a specific format is prescribed, upload the respective freetext template if available from the drop-down list or copy it from the corresponding document.
Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
A Cross-reference to other study or other studys can be included which are considered relevant in the interpretation of the test results, e.g. for supporting the conclusion that an effect observed was not substance-related. Indicate the respective chapter(s) and record ID(s) and enter relevant explanatory text.
Such cross-references may be useful if it is considered relevant to discuss other results at the summary level of a single study. It should be noted that the overall appraisal of results from different studys is normally done in the hazard or risk assessment.
Note that any such cross-reference may become useless if a record is either printed or exchanged on its own.
In the following, the online help texts for all data entry fields provided with any Endpoint study record for this IUCLID section are listed. For sections 4 to 10, these guidance notes are completely based on the so-called OECD Harmonised Templates (see Rationale behind IUCLID Endpoint Study Records - OECD harmonised templates in chapter chapter D.4.7.1 What is an Endpoint study record?)
IUCLID per se does not prescribe how detailed the study summaries should be recorded. Refer to the relevant guidance for the respective chemical regulatory programme thereof.
For technical guidance on how to manage Endpoint study records, see chapter D.4.7 How to manage Endpoint study records in sections 4 - 13. For details on data types, see chapter D.4.5 What data types are available for input fields and how are they used?
Under this main heading, fields are subsumed for identifying the purpose of the record (e.g., "key study"), the type of result (e.g., "experimental study"), data waiving indication (if any), reliability indication, and flags for indicating the regulatory purpose envisaged and/or any confidentiality restrictions. This kind of data characterise the relevance of a study summary and are therefore displayed on top of each Endpoint Study Record. For detailed guidance, refer to chapter D.4.7.7.1 Administrative data.
Indicate the bibliographic reference of the study report or publication the study summary is based on. Always enter the primary reference in the first block of fields (i.e. Sort no. = 1), if there are more than one reference to be cited. Copy this block of fields for specifying any other references related to this record (e.g. report of a preliminary study or other documentation). If results of a study report have been published, indicate the full citation of that publication(s) in addition to the reference of the original study.
Table E.409. Field Descriptions
| Reference type | Indicate the type of reference, e.g. "Study report" or "Publication". Select "Other company data" to characterise any unpublished information from a company other than a study report. Select "Grey literature" for any other unpublished information or "other:" and specify. |
| Author(s) (or transferred reference) (Author) | For ease of sorting and searchability use following convention: Surname, Initial (Example 1: White D, Ruehl KJ, Borman SA & Little J. Example 2: Hartley M & Murray W (avoid unnecessary full-stops, commas)). If no individuals are cited as authors, enter name of company or organisation or "Anon." as appropriate. Note that the complete bibliographic reference may appear in this field after migration of unstructured data from existing databases. |
| Year | Enter year of study report or publication. For a study report this field should be completed to include it in any searches, regardless of whether the complete date is given in field "Report date". |
| Title | Include the title of the report. For publications, include the title of the article of a journal or article/chapter of a book (e.g. handbook). |
| Bibliographic source | Not relevant for any study report. For publications or any other literature source (grey literature) specify the following type of information: (i) Title of scientific journal or book (e.g. if handbook); (ii) Volume of journal; (iii) Editor, publisher, place of publication for books or articles in books; (iv) Pagination. Example 1 (journal): J. Agric. Food Chem. 38: 215-227 Example 2 (handbook): In: Lyman WJ (ed.) Handbook of chemical property estimation methods. Environmental behavior of organic compounds. McGraw-Hill Book Company 15.1-15.34, New York. |
| Testing laboratory | Either manually enter the name of the testing laboratory or select it from the picklist. In either case, editing is possible. |
| Report no. | Specify the report number allocated by the testing laboratory. Note that any company-specific study number should be included in the respective field. |
| Owner company | Either manually enter the identity of the company who owns the data or select it from the picklist. In either case, editing is possible. |
| Company study no. | Specify any company study no. if there is such a number and if it is different from the report no. of the testing laboratory. Otherwise leave field empty. |
| Report date | Specify the complete date of the study report, e.g. "2005-05-12" for 12 May 2005. Note that subfield "Year" should be completed in any case for sorting and searching purposes. |
Select appropriate indication for data access. Enter "Not applicable" if the summary consists of information that is commonly accessible such as guidance on safe use.
Indicate as appropriate. Note: "yes" should be selected only if "Data submitter is data owner" or "Data submitter has Letter of Access". Options "yes, but willing to share" or "yes, but not willing to share" may be relevant for specific regulatory programmes where the submitter is requested to indicate whether he is willing to share studies (e.g. with vertebrates).
In the supplementary remarks field, include an explanation as appropriate, i.e. justification for denial of sharing the corresponding study or refer to a document attached that provides justification (e.g. "for justification see attached document X")
A cross-reference can be included to indicate that the same study is recorded in another record. Indicate the respective chapter and record ID and enter relevant explanatory text. This may be useful if specific endpoints of a given study are described in another chapter (e.g. results on reproduction toxicity in case of a combined repeated dose / reproduction toxicity study) or if more than one experiment is described by the same study report, but included in separate records.
Check with the relevant guidance document whether all the methodology details must be repeated or whether a cross-reference to the same study in another chapter may suffice.
Note that any such cross-reference may become useless if a record is either printed or exchanged on its own.
Indicate if study was in vivo or in vitro test. If in vitro test, describe study design in field "Any other information on materials and methods incl. tables" and the results in field "Any other information on results incl. tables". If a specific template for in vitro assays is provided include the data in that template instead.
Indicate according to which test guideline the study was conducted. If no test guideline was explicitly followed, but the methodology used is equivalent or similar to a specific guideline, you can indicate so in the "Qualifier" subfield preceding the field "Guideline".
Copy this block of fields for specifying more than one guideline (e.g. US EPA in addition to OECD guideline).
Table E.410. Field Descriptions
| Qualifier | Select appropriate qualifier, i.e. - "according to" (if a given test guideline was followed); - "equivalent or similar to" (if no test guideline was explicitly followed, but the methodology is equivalent or similar to a specific guideline); - "no guideline followed" (if none of above qualifiers apply. If so, fill in field "Principles of method if other than guideline"); - "no guideline available" (if so, fill in field "Principles of method if other than guideline"). - "no guideline required" (if so, fill in field "Principles of method if other than guideline"). |
| Guideline | Select the applicable test guideline, e.g. "OECD Guideline xxx". If the test guideline used is not listed, choose "other guideline:" and specify the test guideline in the related text field. In this text field, you can also enter any remarks as applicable, particularly: - To include any other title of the test guideline draft used, a subtitle, another version or update number and the year of update (For instance, different titles and/or numbers may exist for a given EU test guideline.); - To indicate if a the study was performed prior to the adoption of the test guideline specified; - To indicate if the methodology used was based on an extension of the test guideline specified. |
| Deviations from guideline (Deviations) | For robust study summaries or as requested by the regulatory programme, indicate if there are any deviations from the test guideline specified. If "yes" is selected, only briefly state relevant deviations in the supplementary remarks field (e.g. "other species used"); details should be described in the respective fields of the section MATERIALS AND METHODS. |
If no guideline was followed, include a description of the principles of the test protocol or estimated method used in the study. Details should be entered in appropriate distinct fields of section MATERIALS AND METHODS if available. Also provide a justification for using this method if appropriate.
If an estimation method was used (to be indicated in field "Test result type") state the equation(s) and/or computer software or other methods applied to calculate the value(s).
Indicate whether the study was conducted following Good Laboratory Practice or not. Select "yes (incl. certificate)" if a GLP certificate of a test facility is available. Select "yes" if a GLP compliance statement is available, but no information on a GLP certificate. You can give an explanation in the supplementary remarks field, e.g. for explaining why GLP was not complied with or for specifying which (national) GLP was followed.
Indicate if the test material used in the study is equivalent to the submission substance identity. If "yes" is selected, the corresponding identity is automatically entered in the subsequent block of fields "Test material identity".
If "no" is selected, identify the test material in the subsequent block of fields "Test material identity". In this case, also make sure that the information entered in field "Study result type" is consistent, i.e. "read-across from supporting substance (structural analogue or surrogate)".
NOTE: If a completed record is used for another submission, you may have to update both fields "Study result type" and "Test material equivalent to submission substance identity".
If the identity of the test material used for this study is not included in this block of fields automatically, indicate the identity for one or more appropriate identifiers, e.g. CAS number, CAS name, IUPAC name. Copy this block of fields as appropriate.
If another than the submission substance identity was selected erraneously, go back to field "Test material equivalent to submission substance identity" and select "yes". This will prompt automatic entry of the respective identifiers.
Table E.411. Field Descriptions
| Identifier | Select an appropriate identifier from drop-down list, e.g. "CAS number". Use "Other:" and specify, if identity according to a standard identifier is not known or if an additional chemical name or number is provided. |
| Identity | Select the corresponding substance identity from drop-down list or enter manually if the identity is not available from the list or if no list is provided for the type of identifier selected. |
Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Note that any information that can be claimed confidential should be included in the subsequent field "Confidential details on test material".
Explanations:
- Name of test material (as cited in study report): only if different from any other identifiers provided in the preceding fields.
- Molecular formula (if other than submission substance): specify
- Molecular weight (if other than submission substance): specify
- Smiles notation (if other than submission substance): provide if available
- InChl (if other than submission substance): provide if available
- Structural formula attached as image file (if other than submission substance): see Fig.: only if different from submission substance. Indicate Fig. no. if a file is attached in field "Attached document", e.g. state "see Fig. 1".
- Substance type: indicate whether pure active substance, technical product, formulation or other.
- Physical state: indicate "gas", "solid" or "liquid" only if different from submission substance or if substance can occur in different physical states.
- Analytical purity: specify in %
- Impurities (identity and concentrations): specify
- Composition of the test material, percentage of components: specify if applicable
- Isomers composition: specify if applicable
- Purity test date: provide if available
- Lot/batch No.: provide if available
- Expiration date of the lot/batch: provide if available
- Radiochemical purity (if radiolabelling): specify if applicable
- Specific activity (if radiolabelling): specify if applicable
- Locations of the label (if radiolabelling): specify if applicable
- Expiration date of radiochemical substance (if radiolabelling): specify if applicable
- Storage condition of test substance: specify if applicable
- Stability under test conditions: indicate if available
Enter any confidential information on the test material in this separate field. Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Explanations:
- Analytical purity: specify in %
- Impurities (identity and concentrations): specify
- Composition of the test material, percentage of components: specify if applicable
- Purity test date: provide if available
- Lot/batch No.: : provide if available
- Expiration date of the lot/batch: : provide if available
- Isomers composition: specify if applicable
Select as appropriate. For in vitro tests, indicate the species used as source of the test system. If not available from picklist, select "other" and specify.
NOTE: Although species "human" is provided in the picklist for specifying the source of in vitro test systems as applicable, human data should be reported in an appropriate subsection of section "Exposure related observations", particularly subsection "Sensitisation data".
It can be useful to document, in section "Respiratory sensitisation", that human data are provided by creating a record and referring to the human data in field "Cross-reference to same study". This could be relevant if lack of animal experiments is defended by the availability of data on experience with human exposure.
Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) as to whether human data should be referenced in the appropriate endpoint summary record.
Select strain as appropriate. If not available from picklist, select "other" and specify.
Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Explanations:
- Diet: Describe type of diet (e.g. conventional laboratory diet / caloric restriction) and whether it was provided ad libitum.
- Water: Describe type (e.g. drinking water) and whether it was provided ad libitum.
- IN-LIFE DATES: If required, specify the in-life dates (i.e. the phase of a study following treatment in which the test system is alive/growing).
Indicate the route of induction exposure. Remarks can be entered in the supplementary remarks field.
Indicate the route of challenge exposure. Remarks can be entered in the supplementary remarks field.
Select "unchanged (no vehicle)" if none was used or select vehicle used if any.
For each exposure phase (i.e. induction/challenge) provide the doses / concentrations of the test substance applied including unit.
Provide number of animals per dose or state if different numbers were used, e.g. "3 (controls), 5 (in test groups)".
Describe any range finding tests (pilot study) and for the main study the induction and challenge procedures including the type of information given in the freetext template. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Discuss the use of a challenge (i.e. naive) control group: number and sex of animals, dose for challenge application.
Indicate the positive control substance(s) used (i.e. substances known to cause respiratory sensitisation in animals) and give additional remarks in supplementary field as appropriate. If not listed, use "other:" and specify or select "none" or "no data" as applicable.
Copy this field if more than one substance was used.
Indicate the negative control substance(s) used (i.e. substances known to lack the ability to cause respiratory sensitisation in animals) and give additional remarks in supplementary field as appropriate. If not listed, use "other:" and specify or select "none" or "no data" as applicable.
Copy this field if more than one substance was used.
In this field, you can enter any information on materials and methods, for which no distinct field is available, or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
Report the results of the test(s) performed. Include an interpretation of the results in field "Conclusions".
Discuss the positive control results and demonstrate that the laboratory has the capability to identify substances known to cause respiratory sensitisation in animals.
Discuss the negative control results and demonstrate that the laboratory has the capability to identify substances known to lack the ability to cause respiratory sensitisation in animals.
In this field, you can enter any other remarks on results. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: Both the "Materials and methods" section and "Results" section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
In this field, you can enter any overall remarks or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
Attach any background document that cannot be inserted in any rich text editor field, particularly image files (e.g. an image of a structural formula).
Copy this block of fields for attaching more than one file.
Table E.412. Field Descriptions
| Attached document | Upload file by clicking the upload icon. As appropriate, enter any additional information, e.g. language. The file name is displayed after uploading the document. |
| Remarks | As appropriate, include remarks, e.g. a short description of the content of the attached document if the file name is not self-explanatory. |
If required, an electronic copy of the full study report can be attached as WORD, pdf or other document type, which will not be integrated in any report, but must be handled as separate files.
Note: In the export administration you can indicate whether the attached files should be included in the data export or not.
Indicate overall interpretation of test results as given in the study report or as concluded by the submitter. Use supplementary remarks field for indicating if conclusions originally reported were changed by submitter.
Note that a classification in the strict sense is normally not based on an individual study, but includes a weight of evidence evaluation of all relevant data. However, if a single study is used for a classification, you can indicate this In the supplementary remarks field.
If required by the respective national/regional programme, briefly summarise the relevant aspects of the study including the conclusions reached. If a specific format is prescribed, upload the respective freetext template if available from the drop-down list or copy it from the corresponding document.
Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
A Cross-reference to other study or other studys can be included which are considered relevant in the interpretation of the test results, e.g. for supporting the conclusion that an effect observed was not substance-related. Indicate the respective chapter(s) and record ID(s) and enter relevant explanatory text.
Such cross-references may be useful if it is considered relevant to discuss other results at the summary level of a single study. It should be noted that the overall appraisal of results from different studys is normally done in the hazard or risk assessment.
Note that any such cross-reference may become useless if a record is either printed or exchanged on its own.